Presentation is loading. Please wait.

Presentation is loading. Please wait.

OBSERVE-5: Observational postmarketing safety surveillance registry of etanercept for the treatment of psoriasis final 5-year results  Alexa B. Kimball,

Published bySuparman Lie Modified over 6 years ago

Similar presentations

Presentation on theme: "OBSERVE-5: Observational postmarketing safety surveillance registry of etanercept for the treatment of psoriasis final 5-year results  Alexa B. Kimball,"— Presentation transcript:

1 OBSERVE-5: Observational postmarketing safety surveillance registry of etanercept for the treatment of psoriasis final 5-year results  Alexa B. Kimball, MD, Kenneth J. Rothman, DrPH, Gregory Kricorian, MD, David Pariser, MD, Paul S. Yamauchi, MD, PhD, Alan Menter, MD, Craig F. Teller, MD, Girish Aras, PhD, Neil A. Accortt, PhD, Michele Hooper, MD, Kara Creamer Rice, MS, Joel M. Gelfand, MD, MSCE  Journal of the American Academy of Dermatology  Volume 72, Issue 1, Pages (January 2015) DOI: /j.jaad Copyright © 2014 American Academy of Dermatology, Inc. Terms and Conditions

2 Fig 1 Plaque psoriasis. Etanercept status by visit. The number of patients remaining in the study (black bars) and those who remained on etanercept therapy (white bars) throughout the 5-year study is shown. BL, Baseline. Journal of the American Academy of Dermatology  , DOI: ( /j.jaad ) Copyright © 2014 American Academy of Dermatology, Inc. Terms and Conditions

3 Fig 2 Plaque psoriasis. Effectiveness outcomes. The percentage of psoriasis-affected body surface area (BSA) (A); percentage of patients with physician global assessment (PGA) status of clear/almost clear (score 0/1) (B); and mean Dermatology Life Quality Index (DLQI) total score (C) for all patients (squares), patients on continuous etanercept (ETN) (circles), and patients on ETN who had a 0- to 30-day (open triangles) or 0- to 60-day (closed triangles) gap in therapy. Data are presented as observed without imputation for missing data. Journal of the American Academy of Dermatology  , DOI: ( /j.jaad ) Copyright © 2014 American Academy of Dermatology, Inc. Terms and Conditions

Download ppt "OBSERVE-5: Observational postmarketing safety surveillance registry of etanercept for the treatment of psoriasis final 5-year results  Alexa B. Kimball,"

Similar presentations

Secukinumab sustains early patient-reported outcome benefits through 1 year: Results from 2 phase III randomized placebo-controlled clinical trials comparing.

Secukinumab sustains early patient-reported outcome benefits through 1 year: Results from 2 phase III randomized placebo-controlled clinical trials comparing.
Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial  Diamant.

Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial  Diamant.
Lauren Kwa, BA, Jonathan I. Silverberg, MD, PhD, MPH 

Lauren Kwa, BA, Jonathan I. Silverberg, MD, PhD, MPH 
Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to- severe plaque psoriasis up to 1 year: Results from the CLEAR study 

Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to- severe plaque psoriasis up to 1 year: Results from the CLEAR study 
Acute transverse myelitis during treatment with etanercept for severe plaque psoriasis  Juan Escalas, PhD, MD, Nicole Knöpfel, MD, Ana Martin-Santiago,

Acute transverse myelitis during treatment with etanercept for severe plaque psoriasis  Juan Escalas, PhD, MD, Nicole Knöpfel, MD, Ana Martin-Santiago,
Yul W. Yang, MD, PhD, David J. DiCaudo, MD 

Yul W. Yang, MD, PhD, David J. DiCaudo, MD 
Cutaneous myiasis associated with scalp psoriasis

Cutaneous myiasis associated with scalp psoriasis
Five-year analysis from the ESPRIT 10-year postmarketing surveillance registry of adalimumab treatment for moderate to severe psoriasis  Alan Menter,

Five-year analysis from the ESPRIT 10-year postmarketing surveillance registry of adalimumab treatment for moderate to severe psoriasis  Alan Menter,
Megan Wood, MD, Tom Raisanen, MD, Ingrid Polcari, MD 

Megan Wood, MD, Tom Raisanen, MD, Ingrid Polcari, MD 
Efficacy of simvastatin in plaque psoriasis: A pilot study

Efficacy of simvastatin in plaque psoriasis: A pilot study
Sarah Sung, MD, Alexa B. Kimball, MD, MPH 

Sarah Sung, MD, Alexa B. Kimball, MD, MPH 
Surveillance and assessment of occupational dermatitis using Rhode Island workers' compensation data 1998 to 2002  Irwin B. Horwitz, PhD, Brian P. McCall,

Surveillance and assessment of occupational dermatitis using Rhode Island workers' compensation data 1998 to 2002  Irwin B. Horwitz, PhD, Brian P. McCall,
Vaishali Patel, PharmD, Elizabeth J. Horn, PhD, Steve J

Vaishali Patel, PharmD, Elizabeth J. Horn, PhD, Steve J
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to.

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to.
OPA-15406, a novel, topical, nonsteroidal, selective phosphodiesterase-4 (PDE4) inhibitor, in the treatment of adult and adolescent patients with mild.

OPA-15406, a novel, topical, nonsteroidal, selective phosphodiesterase-4 (PDE4) inhibitor, in the treatment of adult and adolescent patients with mild.
The impact of secukinumab treatment on the prevalence of human papillomavirus in patients with psoriasis: A pilot study  Hsien-Yi Chiu, MD, Tsen-Fang.

The impact of secukinumab treatment on the prevalence of human papillomavirus in patients with psoriasis: A pilot study  Hsien-Yi Chiu, MD, Tsen-Fang.
Treatment of notalgia paresthetica with botulinum toxin A: A double-blind randomized controlled trial  Catherine Maari, MD, FRCPC, Philippe Marchessault,

Treatment of notalgia paresthetica with botulinum toxin A: A double-blind randomized controlled trial  Catherine Maari, MD, FRCPC, Philippe Marchessault,
Sara A. Farber, BA, Sara Samimi, MD, Misha Rosenbach, MD 

Sara A. Farber, BA, Sara Samimi, MD, Misha Rosenbach, MD 
The efficacy of multiple courses of alefacept in patients with moderate to severe chronic plaque psoriasis  Alan Menter, MD, Jennifer C. Cather, MD, Diane.

The efficacy of multiple courses of alefacept in patients with moderate to severe chronic plaque psoriasis  Alan Menter, MD, Jennifer C. Cather, MD, Diane.
Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled.

Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled.

Similar presentations

Ads by Google